Source: Journal of Clinical Oncology. Conference titles: Gastrointestinal Cancers Symposium. Unidade: FM
Subjects: TAXA DE SOBREVIVÊNCIA, NEOPLASIAS COLORRETAIS, METÁSTASE NEOPLÁSICA
ABNT
COART, Elisabeth et al. Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1200/jco.2015.33.3_suppl.666. Acesso em: 03 jun. 2024. , 2015APA
Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Zalcberg, J. R., Maughan, T., et al. (2015). Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1200/jco.2015.33.3_suppl.666NLM
Coart E, Saad ED, Shi Q, Sommeijer DW, Zalcberg JR, Maughan T, Goldberg RM, Schmoll H-J, Punt CJA, Cutsem EV, Douillard J-Y, Hoff PM, Tebbutt NC, Fuchs CS, Falcone A, Tournigand C, De Gramont A, Sargent DJ, Burzykowski T, Buyse ME. Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 jun. 03 ] Available from: https://doi.org/10.1200/jco.2015.33.3_suppl.666Vancouver
Coart E, Saad ED, Shi Q, Sommeijer DW, Zalcberg JR, Maughan T, Goldberg RM, Schmoll H-J, Punt CJA, Cutsem EV, Douillard J-Y, Hoff PM, Tebbutt NC, Fuchs CS, Falcone A, Tournigand C, De Gramont A, Sargent DJ, Burzykowski T, Buyse ME. Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2024 jun. 03 ] Available from: https://doi.org/10.1200/jco.2015.33.3_suppl.666